1. Home
  2. NREF vs PROK Comparison

NREF vs PROK Comparison

Compare NREF & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NexPoint Real Estate Finance Inc.

NREF

NexPoint Real Estate Finance Inc.

HOLD

Current Price

$17.75

Market Cap

296.5M

Sector

Real Estate

ML Signal

HOLD

Logo ProKidney Corp.

PROK

ProKidney Corp.

HOLD

Current Price

$2.04

Market Cap

316.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NREF
PROK
Founded
2019
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
296.5M
316.0M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
NREF
PROK
Price
$17.75
$2.04
Analyst Decision
Hold
Strong Buy
Analyst Count
2
5
Target Price
$14.00
$7.40
AVG Volume (30 Days)
38.1K
1.2M
Earning Date
04-30-2026
05-08-2026
Dividend Yield
13.95%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$893,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$10.47
N/A
P/E Ratio
$4.78
N/A
Revenue Growth
N/A
1075.00
52 Week Low
$12.36
$1.30
52 Week High
$18.43
$3.48

Technical Indicators

Market Signals
Indicator
NREF
PROK
Relative Strength Index (RSI) 60.22 71.06
Support Level $16.39 $1.56
Resistance Level $18.27 $2.22
Average True Range (ATR) 0.47 0.12
MACD 0.02 0.05
Stochastic Oscillator 71.67 92.25

Price Performance

Historical Comparison
NREF
PROK

About NREF NexPoint Real Estate Finance Inc.

NexPoint Real Estate Finance Inc is a commercial mortgage REIT focused on generating attractive, risk-adjusted returns for shareholders over the long term. The company invests mainly in first-lien mortgage loans, mezzanine loans, preferred equity, multifamily properties, and common equity investments, as well as multifamily and single-family rental CMBS securitizations, promissory notes, revolving credit facilities, and stock warrants. It focuses on real estate sectors where its management has operating expertise, including multifamily, single-family rental, self-storage, industrial, and life sciences, mainly in top metropolitan areas.

About PROK ProKidney Corp.

ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.

Share on Social Networks: